VIRX vs. COYA, IMUX, PDSB, CLRB, CYTT, DMAC, BYSI, ALLK, VTGN, and CLSD
Should you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Coya Therapeutics (COYA), Immunic (IMUX), PDS Biotechnology (PDSB), Cellectar Biosciences (CLRB), Cyteir Therapeutics (CYTT), DiaMedica Therapeutics (DMAC), BeyondSpring (BYSI), Allakos (ALLK), Vistagen Therapeutics (VTGN), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical preparations" industry.
Viracta Therapeutics (NASDAQ:VIRX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Coya Therapeutics has higher revenue and earnings than Viracta Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viracta Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Coya Therapeutics' return on equity of -45.11% beat Viracta Therapeutics' return on equity.
In the previous week, Coya Therapeutics had 4 more articles in the media than Viracta Therapeutics. MarketBeat recorded 5 mentions for Coya Therapeutics and 1 mentions for Viracta Therapeutics. Coya Therapeutics' average media sentiment score of 1.29 beat Viracta Therapeutics' score of 1.14 indicating that Coya Therapeutics is being referred to more favorably in the news media.
Viracta Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 828.57%. Coya Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 83.73%. Given Viracta Therapeutics' higher possible upside, research analysts plainly believe Viracta Therapeutics is more favorable than Coya Therapeutics.
Viracta Therapeutics received 19 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 88.89% of users gave Coya Therapeutics an outperform vote while only 72.97% of users gave Viracta Therapeutics an outperform vote.
31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 12.0% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Coya Therapeutics beats Viracta Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Viracta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viracta Therapeutics Competitors List
Related Companies and Tools
